Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase

• US 9,150,543 B2
• Filed: 04/03/2014
• Issued: 10/06/2015
• Est. Priority Date: 07/28/2004
• Status: Active Grant

• Current Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Original Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Inventors: Verdonck, Marc Gustaaf Celine, Angibaud, Patrick Rene, Roux, Bruno, Pilatte, Isabelle Noelle Constance, Ten Holte, Peter, Arts, Janine, Van Emelen, Kristof
• Primary Examiner(s): RAO, DEEPAK R
• Application Number:
  US14/244,046
• Publication Number:
  US 20140309248A1
• Time in Patent Office: 551 Days
• Field of Search: 514/275, 544/331
• US Class Current: 1/1
• CPC Class Codes: A61K 31/454 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 409/14 containing three or more hetero rings
• CPC Class Codes: C07D 491/04 Ortho-condensed systems
• CPC Class Codes: C07D 491/056 with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Abstract

This invention comprises the novel compounds of formula (I)

wherein R¹, R², R³, X and Y have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.

Claims

1. A method of treating non-Small cell lung cancer in a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of formula (I),

2. The method of claim 1 in which the non-cell lung cancer is caused by histone deacetylase (HDAC) activity.

4. The method of claim 1, wherein the compound of formula I is

3. A method of inhibiting tumor growth in a subject having non-small cell lung cancer comprising administering to the subject a therapeutically effective amount of the compound of formula (I),

5. The method of claim 3, wherein the compound of formula I is